Clinical and economic considerations of vaccination against varicella

Pharmacotherapy

Volumn 17, Issue 1, 1997, Pages 133-139

  Strassels, Scott A ^a,b   Sullivan, Sean D ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHICKENPOX VACCINE;

CHICKENPOX; CHILD; COST BENEFIT ANALYSIS; DRUG COST; DRUG EFFICACY; HERPES ZOSTER; HUMAN; IMMUNE DEFICIENCY; REVIEW; VACCINATION; VARICELLA ZOSTER VIRUS;

ADOLESCENT; ADULT; CHICKENPOX; CHICKENPOX VACCINE; CHILD; COST-BENEFIT ANALYSIS; HUMANS; INFANT; INFANT, NEWBORN; UNITED STATES; VACCINATION;

EID: 0031028436     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (24)

1. American Academy of Pediatrics, Committee on Infectious Disease. Recommendations for the use of live attenuated varicella vaccine. Pediatrics 1995;95(5):791-6.
2. Preblud SR, Orenstein WA, Koplan JP, Bart KJ, Hinman AR. A benefit-cost analysis of a childhood varicella vaccination programme. Postgrad Med J 1985;61(suppl 4):17-22.
3. Takahashi M, Otsuka T, Okuno Y, Asano Y, Yazaki T, Isomura S. Live vaccine used to prevent the spread of varicella in children in hospital. Lancet 1974;2:1288-90.
4. Dudley MN. Management of herpesvirus infections in the healthy host. Pharmacotherapy 1995;15(5 Pt 2):43S-8.
5. Whitley RJ. Varicella-zoster virus. In: Mandell GL, Bennett JE, Dolin R, eds. Mandell, Douglas and Bennett's principles and practice of infectious diseases, 4th ed. New York: Churchill Livingstone, 1995:1345-50.
6. Centers for Disease Control and Prevention. Summary of notifiable diseases, United States, 1994. MMWR 1994;43(53):80.
7. Asano Y, Nagai T, Miyata T, et al. Long-term protective immunity of recipients of the OKA strain of live varicella vaccine. Pediatrics 1985;75:667-71.
8. Weibel RE, Neff BJ, Kuter BJ, et al. Live attenuated varicella virus vaccine efficacy trial in healthy children. N Engl J Med 1984;310:1409-15.
9. Kuter BJ, Weibel RE, Guess HA, et al. Oka/Merck varicella vaccine in healthy children: final report of a 2-year efficacy study and 7-year follow-up studies. Vaccine 1991;9(9):643-7.
10. White CJ, Kuter BJ, Ngai A, et al. Modified cases of chickenpox after varicella vaccination: correlation of protection with antibody response. Pediatr Infect Dis J 1992;11:19-23.
11. Merck & Co. Varivax (varicella virus vaccine live [Oka/Merck]) package insert. West Point, PA; 1995.
12. Abramowicz M, ed. Varicella vaccine. Med Lett Drugs Ther 1995;37(951):55-7.
13. Wharton M, Cochi SL, Williams WW. Measles, mumps, and rubella vaccines. Infect Dis Clin North Am 1990;4(1):47-73.
14. Haas RJ, Belohradsky B, Dickerhoff R, et al. Active immunization against varicella of children with acute leukaemia or other malignancies on maintenance chemotherapy. Postgrad Med J 1985;61(suppl 4):69-72.
15. Gershon AA, Steinberg S, Gelb L, et al. A multicentre trial of live attenuated varicella vaccine in children with leukaemia in remission. Postgrad Med J 1985;61(suppl 4):73-8.
16. Huse DM, Meissner HC, Lacey MJ, Oster G. Childhood vaccination against chickenpox: an analysis of benefits and costs. J Pediatr 1994;124:869-74.
17. Lieu TA, Cochi SL, Black SB, et al. Cost-effectiveness of a routine varicella vaccination program for US children. JAMA 1994;271:375-81.
18. Lieu TA, Black SB, Rieser N, Ray P, Lewis EM, Shinefeld HR. The cost of childhood chickenpox: parents' perspective. Pediatr Infect Dis J 1994;13:173-7.
19. Lieu TA, Finkler LJ, Sorel ME, Black SB, Shinefeld HR. Cost-effectiveness of varicella serotesting versus presumptive vaccination of school-age children and adolescents. Pediatrics 1995;95:632-8.
20. Kitai IC, King S, Gafni A. An economic evaluation of varicella vaccine for pediatric liver and kidney recipients. Clin Infect Dis 1993;17:441-7.
21. Weber DJ, Rutala WA, Parham C. Impact and costs of varicella prevention in a university hospital. Am J Public Health 1988;78:19-23.
22. Dennehy PH. Varicella vaccine for prevention of chickenpox. RI Med 1995;78:14-16.
23. Krahn M, Gafni A. Discounting in the economic evaluation of health care interventions. Med Care 1993;31(5):403-18.
24. Bloom BS, Hillman AL, Fendrick AM, Schwartz JS. A reappraisal of hepatitis B virus vaccination strategies using cost-effectiveness analysis. Ann Intern Med 1993;118:298-30.